Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: A comparative PET study with [11C]raclopride and [11C]N- methylspiperone

Journal of Nuclear Medicine

Volumn 41, Issue 1, 2000, Pages 65-70

  Kaasinen, Valtteri ^b   Ruottinen, Hanna M ^b   Någren, Kjell ^b   Lehikoinen, Pertti ^b   Oikonen, Vesa ^b   Rinne, Juha O ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b NONE

Author keywords

Dopamine D2 receptor; N methylspiperone; Parkinson's disease; PET; Raclopride

Indexed keywords

3 METHYLSPIPERONE C 11; DOPAMINE 2 RECEPTOR; RACLOPRIDE; RACLOPRIDE C 11; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC VALUE; FEMALE; HUMAN; LIGAND BINDING; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR UPREGULATION;

CARBON RADIOISOTOPES; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; RACLOPRIDE; RECEPTORS, DOPAMINE D2; SPIPERONE; TOMOGRAPHY, EMISSION-COMPUTED; UP-REGULATION;

EID: 0033957270     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Rinne UK, Laihinen A, Rinne JO, Någren K, Bergman J, Ruotsalainen U. Positron emission tomography (PET) demonstrates dopamine D-2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord. 1990;5:55-59.
2. Rinne JO, Laihinen A, Någren K, et al. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. J Neurosci Res. 1990;27:494-499.
3. 11C]raclopride [abstract]. Neurology. 1991;41(suppl 1):211.
4. 2 receptor changes during the progression of early Parkinson's disease. Mov Disord. 1993;8:134-138.
5. Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RSJ. Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projections in dopa naïve parkinsonism. Brain. 1993;116:853-867.
6. 2 receptor density is inversely correlated with dopaminergic innervation in untreated Parkinson's disease [abstract]. Neurology. 1993;43(suppl):269.
7. 11C]raclopride. J Neurol Sci. 1995;132:156-161.
8. 3H]raclopride: implications for positron emission tomography of the human brain. Synapse. 1989;3:96-97.
9. 3H]raclopride binding in the rat brain. Synapse. 1991;9:188-194.
10. 3H-raclopride. J Neural Transm. 1988;73:7-21.
11. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse. 1993;13:350-356.
12. 3H]raclopride to rat and human brain membranes. J Neurochem. 1990;55:2048-2057.
13. Fahn S, Elton RL, and the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Healthcare Information; 1987:153-163.
14. Halldin C, Farde L, Högberg T, et al. A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides: preparation and in vitro dopamine D-2 receptor binding. Nucl Med Biol 1991;18:871-881.
15. 11C-raclopride. J Cereb Blood Flow Metab. 1993;13:310-314.
16. 11C]methionine. J Labelled Cpd Radiopharm. 1998;41:831-841.
17. 11C-labelled ethyl, propyl, butyl and isobutyl iodides and examples of alkylation reactions. Appl Radiat Isot. 1986;37:1141-1145.
18. 11C]methyl triflate. Appl Radiat Isot. 1992;43:1383-1385.
19. 11C]methyl triflate. Nucl Med Biol. 1995;22:235-239.
20. Pellizari, CA, Chen GTY, Spelbring DR, Weichselbaum RR, Chen CT. Accurate three-dimensional registration of CT, PET, and/or MR images of the brain. J Comp Assist Tomogr. 1989;13:20-26
21. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
22. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple time uptake data: generalizations. J Cereb Blood Flow Metab. 1985;5:584-590
23. 11C-N-methyl-spiperone. Acta Neurol Scand. 1987;75:87-94.
24. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
25. 11C-raclopride and positron emission tomography. Ann Neurol. 1992;31:184-192.
26. 2-receptors. Neurology. 1994;44:1325-1329.
27. Creese I, Burt DR, Snyder SH. Dopamine receptor binding enhancement accompanies lesion-induced behavioural supersensitivity. Science. 1977;197:596-598.
28. Leenders KJ, Aquilonius SM, Bergström K, et al. Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res. 1988;445:61-67.
29. Tedroff J. Parkinson's Disease: Pathophysiology and PET [dissertation]. Uppsala, Sweden: Uppsala Universitet; 1990.
30. Calne DB, Langston JW, Martin WR, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature. 1985;317:246-248.
31. Perlmutter JS, Kilbourn MR, Raichle ME, Welch MJ. MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans. Neurology. 1987;37:1575-1579.
32. 2 dopamine receptors in Parkinson's diseased striatum. J Neural Transm. 1985;64:93-103.
33. Lee T, Seeman P, Rajput A, Farley IJ, Homykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature. 1978;273:59-61.
34. Rinne UK, Koskinen V, Lönnberg P. Dopamine receptors in the parkinsonian brain. J Neural Transm. 1981;51:97-106.
35. 11C-raclopride PET findings in patients with parkinsonism. Nucl Med Commun. 1994;15:806-813.
36. 2 serotonin receptors in cerebral cortex. J Neurosci. 1986;6:2941-2949.